SERENACE

SECTION 2: Hazards identification

Appearance: Clear, colorless solution

Additional information

Short Term: Overdose: Seizure and/or coma may oceur. Long Term: Animal studies have shown a potential to cause adverse effects on the fetus. Repeat-dose studies in animals have shown a potential to cause adverse effects on reproductive system. Can cause effects on central nervous system, gastrointestinal , cardiovascular system and respiratory system. Known Clinical Effects: Therapeutic use of this substance has resulted in weakness, dizziness, drowsiness, ataxia, confusion, tremars, headache, and gastrointestinal disturbances. As with alt antipsychotic agents, tardive dyskinesia may appear. This syndrome is characterized by rhythmical involuntary movements of the tongue, face, mouth, or jaw. Higher doses may cause CNS stimulation and/or depression, and impairment of motor and cognitive skills. EU indication of danger: Not classified Australian Hazard Classification Non-Hazardous Substance. Non-Dangerous Goods. {NOHSC): Note: This document has been prepared in accordance with standards for workplace safety, which require the Inclusion of all known hazards of the active substance or its intermediates regardiess of the potential risk. The precautionary statements and wamings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace. ] Hazardous Ingredient CAS Number _|EU EINECS/ELINCS List| EU Classification % [Haloperidol 52-86-8 200-155-6 T,R25 0.49 Repr.Cat2;R60 Repr.Cat2;R61 Lactic acid 50-21-5 200-018-0 Not Listed * Ingredient CAS Number |EU EINECS/ELINCS List| EU Classification % } lucose 50-99-7 200-075-1 Not Listed * iter for Injection 7732-185 231-791-2 Not Listed * Additional tnformation: * Proprietary Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. For the full text of the R phrases mentioned in this Section, see Section 16